Site icon OncologyTube

Preclinical Data Supporting the Combination of VS-6766 and Defactinib – J. Silvio Gutkind PhD – In Conclusion – UC San Diego @UCSDHealth #headandneckcancer

J. Silvio Gutkind, PhD – UC San Diego discusses Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma AACR https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-presentation-preclinical-data-0

 

You may also be interested in:

VS-6766 + Defactinib in Non-Small Cell Lung Cancer 

Exit mobile version